Optimization and simplification of antiretroviral therapy for adults and children

Current Opinion in HIV and AIDS

Volumn 8, Issue 6, 2013, Pages 591-599

  Ford, Nathan ^a   Flexner, Charles ^b   Vella, Stefano ^c   Ripin, David ^d   Vitoria, Marco ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d CLINTON HEALTH ACCESS INITIATIVE   (United States)

Author keywords

antiretroviral therapy; fixed dose combination; integrase inhibitors; regimen simplification

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APRICITABINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BMS 663068; CENICRIVIROC; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR; DOLUTEGRAVIR; DORAVIRINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; FESTINAVIR; GSK 1265744; IBALIZUMAB; INTEGRASE INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR 3 HEXADECYLOXYPROPYL ESTER; TENOFOVIR ALAFENAMIDE; TMB 355; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMORBIDITY; HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84886085797     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000010     Document Type: Review

References (37)

1. Duncombe C, Ball A, Passarelli C, Hirnschall G. Treatment 2.0: catalyzing the next phase of treatment, care and support. Curr Opin HIV AIDS 2013; 8:4-11.
2. van t Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (tmc278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042-2050.
3. Min S, DeJesus E, McCurdy L, et al. Pharmacokinetics (PK) and safety in health and HIV-infected subjects and shot-term antiviral efficacy of s/GSK 1265744, a next generation once-daily HIV integrase inhibitor. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting; 12-15 September 2009, San Francisco.
4. Crawford KW, Ripin DH, Levin AD, et al. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12:550-560.
5. Le Douce V, Janossy A, Hallay H, et al. Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother 2012; 67:1063-1074.
6. Lafeuillade A. Eliminating the HIV reservoir. Curr HIV/AIDS Rep 2012; 9:121-131.
7. Mugavero MJ, Napravnik S, Cole SR, et al. Centers for Aids Research Network of Integrated Clinical Systems (CNICS) Cohort Study. Viremia copy-years predicts mortality among treatment-naive hiv-infected patients initiating antiretroviral therapy. Clin Infect Dis 2011; 53:927-935.
8. Phillips A. Morbidity and mortality in the HAART era. In: 15th conference on retroviruses and opportunistic infections; Boston; 2008 Abstract 8.
9. Tseng Z, Secemsky E, Dowdy D, et al. Sudden cardiac death in patients with HIV. J Am Coll Cardiol 2012; 59:1891-1896.
10. Kuller LH, Tracy R, Belloso W, et al. Insight Smart Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:E203.
11. Heaton R, Deutsch R, Franklin D, et al., and the Charter Group. Prevalence and predictors of neurocognitive decline over 18 to 42 months: a charter longitudinal study. In: 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012, Seattle. Abstract 474.
12. Ellis R, Heaton R, Letendre S, et al. Higher CD4 nadir is associated with reduced rates of HIV-associated neurocognitive disorders in the charter study: potential implications for early treatment initiation. In: 17th Conference on Retroviruses and Opportunistic Infections; 2010. Abstract 429.
13. Ho J, Deeks S, Hecht F, et al. Earlier initiation of ART in HIV-infected individuals is associated with reduced arterial stiffness. In: 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010, San Francisco. Abstract 707.
14. Klein D, Leyden W, Xu L, et al. Contribution of immunodeficiency to CHD: cohort study of HIV and HIV- Kaiser Permanente members. In: 18th Conference on Retroviruses and Opportunistic Infections; 27 February-2 March 2011, Boston. Abstract 810.
15. Dao C, Young B, Buchacz K, et al. and The HIV Outpatient Study Investigators. Higher and increasing rates of fracture among HIV-infected persons in the HIV outpatient study compared to the general us population, 1994 to 2008. In: 17th Conference on Retroviruses and Opportunistic Infections; 2010. Abstract 128.
16. Gras L, Kesselring AM, Griffin JT, et al., Athena, Netherlands national observational cohort study. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007; 45:183-192.
17. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
18. HIV-CAUSAL Collaboration. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154:509-515.
19. When To Start Consortium. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
20. Strategic timing of antiretroviral treatment (start). Clinicaltrials.Gov identifier: Nct00867048. http://clinicaltrials.Gov/ct2/show/nct00867048? Termstart &rank1.
21. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 temprano). Clinicaltrials.Gov identifier: Nct00495651. .
22. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 27 March 2012. http://aidsinfo.Nih.Gov/guidelines/html/1/adult-and-adoles cent-treatment-guidelines/.
23. US Food and Drugs Administration. Antiretroviral drugs used in the treatment of HIV infection. http://www.Fda.Gov/forconsumers/byaudience/forpatien tadvocates/hivandaidsactivities/ucm118915.Htm.
24. The 2013 Pipeline report: HIV, HCV and TB drugs, diagnostics, vaccines, and preventive technologies in development. I-base/treatment action group, July 2013.
25. United Nations General Assembly. Political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS. Resolution adopted by the general assembly on 10 June 2011. A/res/65/277.
26. WHO. Programmatic update: use of antiretroviral drugs for treating of pregnant women and preventing HIV infection in infants. Geneva: World Health Organization; 2010; http://whqlibdoc.Who.Int/hq/2012/who-hiv- 2012.8-eng.Pdf..
27. Global HIV/AIDS Response. Epidemic update and health sector progress towards universal access: progress report 2011. Geneva: WHO/UNAIDS/ UNICEF; 2011. 28. Antiretroviral therapy for HIV infection in infants and children: towards universal access: recommendations for a public health approach. 2010 revision.Geneva: WHO;2010; http://whqlibdoc.Who.Int/publications/2010/ 9789241599801-eng.Pdf.
28. Treatment options for protease inhibitor-exposed children (Neverest-III). Clinical trials identifier nct01146873. http://clinicaltrials.Gov/ct2/show/ nct01146873.
29. Loeliger A, Suthar AB, Ripin D, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis 2012; 16:6-15.
30. Alberti A, Clumeck N, Collins S. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
31. Swan T. The hepatitis C treatment pipeline report. New York: Treatment action group 2011; http://www.Treatmentactiongroup.Org/hcv/publications/ 2011/hcvpipeline2011.
32. Jennings CL, Sherman KE. Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Curr HIV/AIDS Rep 2012; 9:231-237.
33. Kredo T, Mauff K, Van der Walt JS, et al. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother 2011; 55:5616-5623.
34. Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67:2213- 2221; d.
35. Peyriere H, Eiden C, Macia J, Reynes J. Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother 2012; 46:703-709.
36. Flynn PM, Rudy BJ, Lindsey JC, et al. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses 2007; 23:1208-1214.
37. Ferrand RA, Corbett EL, Wood R, et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23:2039-2046.